Voyager Therapeutics, Inc. (VYGR)
USD 2.87
(-7.28%)
USD 2.87
(-7.28%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 126.45 Million USD | 348.75% |
| 2022 | -44.64 Million USD | 30.94% |
| 2021 | -68.45 Million USD | -335.95% |
| 2020 | 31.2 Million USD | 160.37% |
| 2019 | -48.91 Million USD | 43.27% |
| 2018 | -88.97 Million USD | -26.76% |
| 2017 | -70.26 Million USD | -74.01% |
| 2016 | -40.68 Million USD | -103.91% |
| 2015 | -19.65 Million USD | -42.8% |
| 2014 | -14.18 Million USD | -10484.33% |
| 2013 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -14.98 Million USD | -127.05% |
| 2024 Q2 | -13.63 Million USD | 9.03% |
| 2023 Q1 | 122.88 Million USD | 600.28% |
| 2023 Q3 | -28.56 Million USD | -17.35% |
| 2023 Q2 | -24.34 Million USD | -119.81% |
| 2023 Q4 | 55.39 Million USD | 293.96% |
| 2023 FY | - USD | 348.75% |
| 2022 FY | - USD | 30.94% |
| 2022 Q2 | -18.16 Million USD | 2.02% |
| 2022 Q3 | 15.78 Million USD | 186.9% |
| 2022 Q4 | -24.56 Million USD | -255.63% |
| 2022 Q1 | -18.53 Million USD | -425.11% |
| 2021 Q3 | -23.92 Million USD | 12.69% |
| 2021 FY | - USD | -335.95% |
| 2021 Q2 | -27.4 Million USD | -12.69% |
| 2021 Q1 | -24.31 Million USD | -6.92% |
| 2021 Q4 | 5.7 Million USD | 123.84% |
| 2020 Q2 | -8.05 Million USD | 65.86% |
| 2020 Q1 | -23.59 Million USD | -71.35% |
| 2020 Q3 | 85.58 Million USD | 1162.56% |
| 2020 Q4 | -22.74 Million USD | -126.57% |
| 2020 FY | - USD | 160.37% |
| 2019 Q2 | 9.86 Million USD | 134.4% |
| 2019 Q3 | -17.09 Million USD | -273.26% |
| 2019 Q4 | -13.76 Million USD | 19.45% |
| 2019 FY | - USD | 43.27% |
| 2019 Q1 | -28.67 Million USD | -23.82% |
| 2018 Q2 | -25.17 Million USD | -22.0% |
| 2018 FY | - USD | -26.76% |
| 2018 Q4 | -23.16 Million USD | -12.54% |
| 2018 Q3 | -20.58 Million USD | 18.26% |
| 2018 Q1 | -20.63 Million USD | -67.13% |
| 2017 Q1 | -17.2 Million USD | -24.3% |
| 2017 FY | - USD | -74.01% |
| 2017 Q4 | -12.34 Million USD | 46.13% |
| 2017 Q3 | -22.92 Million USD | -25.74% |
| 2017 Q2 | -18.23 Million USD | -5.96% |
| 2016 Q1 | -7.33 Million USD | 1.47% |
| 2016 FY | - USD | -103.91% |
| 2016 Q4 | -13.84 Million USD | -35.56% |
| 2016 Q3 | -10.21 Million USD | -7.87% |
| 2016 Q2 | -9.46 Million USD | -29.12% |
| 2015 Q1 | -4.69 Million USD | -7.12% |
| 2015 Q2 | -3.82 Million USD | 18.63% |
| 2015 FY | - USD | -42.8% |
| 2015 Q4 | -7.44 Million USD | -92.8% |
| 2015 Q3 | -3.85 Million USD | -0.97% |
| 2014 FY | - USD | -10484.33% |
| 2014 Q2 | -3.22 Million USD | -8.08% |
| 2014 Q4 | -4.38 Million USD | -22.04% |
| 2014 Q3 | -3.59 Million USD | -11.48% |
| 2014 Q1 | -2.98 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 165.808% |
| Alkermes plc | 495.04 Million USD | 74.456% |
| Agenus Inc. | -145.92 Million USD | 186.658% |
| Aptorum Group Limited | -9.59 Million USD | 1417.377% |
| Ardelyx, Inc. | -55.35 Million USD | 328.448% |
| Dyadic International, Inc. | -8.22 Million USD | 1636.561% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 43555.326% |
| Lantern Pharma Inc. | -15.78 Million USD | 901.023% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 735.057% |
| Novavax, Inc. | -487.39 Million USD | 125.945% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 278.045% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 261.104% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 803.566% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 1368.61% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 320.397% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 133.28% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 624.451% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -23804.537% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 180.445% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 269.024% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 727.288% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 632.779% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 648.421% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 203.564% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 148.968% |
| AlloVir, Inc. | -190.14 Million USD | 166.504% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 171.984% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 532.207% |
| Bicycle Therapeutics plc | -183.4 Million USD | 168.95% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 176.444% |
| ChromaDex Corporation | -3.89 Million USD | 3347.432% |
| Chimerix, Inc. | -92.97 Million USD | 236.011% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 384.573% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 212.37% |
| CRISPR Therapeutics AG | -202.7 Million USD | 162.385% |
| Precision BioSciences, Inc. | -32.04 Million USD | 494.654% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 173.423% |
| Fortress Biotech, Inc. | -133.64 Million USD | 194.621% |
| Fortress Biotech, Inc. | -133.64 Million USD | 194.621% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 263.499% |
| ImmuCell Corporation | -2.5 Million USD | 5149.965% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 196.959% |
| Immix Biopharma, Inc. | -16.13 Million USD | 883.7% |
| Incyte Corporation | 919.42 Million USD | 86.246% |
| Innoviva, Inc. | 248.96 Million USD | 49.207% |
| IO Biotech, Inc. | -91.22 Million USD | 238.614% |
| Jaguar Health, Inc. | -33.13 Million USD | 481.682% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 183.097% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -24.308% |
| ContextLogic Inc. | -324 Million USD | 139.029% |
| MiMedx Group, Inc. | 40.51 Million USD | -212.104% |
| MEI Pharma, Inc. | 26.38 Million USD | -379.359% |
| NextCure, Inc. | -59.03 Million USD | 314.189% |
| Onconetix, Inc. | -36.7 Million USD | 444.501% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -5557.942% |
| Opthea Limited | -200.01 Million USD | 163.222% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 4695.723% |
| Vaxcyte, Inc. | -464.88 Million USD | 127.201% |
| PDS Biotechnology Corporation | -40.08 Million USD | 415.467% |
| Precigen, Inc. | -89.22 Million USD | 241.724% |
| Pharming Group N.V. | 9.87 Million USD | -1180.298% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 179.507% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 655.553% |
| PureTech Health plc | -11.62 Million USD | 1187.598% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 844.685% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 154.157% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 624.451% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 244.641% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 536.609% |
| Acelyrin, Inc. | -381.52 Million USD | 133.145% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 981520.874% |
| Summit Therapeutics Inc. | 1 Million USD | -12532.867% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 478.767% |
| Senti Biosciences, Inc. | -61.33 Million USD | 306.168% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 212.601% |
| Elevation Oncology, Inc. | -41.46 Million USD | 404.953% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 509.187% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 2167.425% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 39494.081% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 489.656% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 1606.134% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 315.096% |
| Seer, Inc. | -97.88 Million USD | 229.187% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 303.314% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 293.46% |
| ESSA Pharma Inc. | -26.45 Million USD | 577.995% |
| GlycoMimetics, Inc. | -39.12 Million USD | 423.233% |
| GT Biopharma, Inc. | 5.97 Million USD | -2014.986% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 161.18% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 1941.22% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -45.665% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 322.812% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 346.891% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 1379.015% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 123.421% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 1936.941% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 369.846% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 153.442% |
| Aptose Biosciences Inc. | -52.26 Million USD | 341.936% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 217.367% |
| Soligenix, Inc. | -7.85 Million USD | 1710.307% |
| Century Therapeutics, Inc. | -121.2 Million USD | 204.329% |
| Kura Oncology, Inc. | -164.95 Million USD | 176.66% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 257.875% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 1353.768% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 13303.493% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 3034.672% |
| Autolus Therapeutics plc | -156.77 Million USD | 180.663% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 249.373% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 283.265% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 734.368% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 166.811% |
| GRI Bio, Inc. | -10.89 Million USD | 1260.351% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 2900.332% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 203.224% |
| IGM Biosciences, Inc. | -253.35 Million USD | 149.912% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 221.835% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 431.614% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 924.837% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 903.234% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 322.456% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 218.069% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 147.54% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 165.203% |
| Verastem, Inc. | -83.16 Million USD | 252.051% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 350.049% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 179.919% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 210.839% |
| Histogen Inc. | -10.5 Million USD | 1303.989% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 985.557% |
| Surrozen, Inc. | -41.13 Million USD | 407.445% |
| Organovo Holdings, Inc. | -14.8 Million USD | 954.079% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -3942993.234% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 315.378% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 346.53% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 687.098% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 1616.61% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 176.147% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 356.717% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 623.277% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 939.951% |
| Apollomics, Inc. | -171.74 Million USD | 173.629% |
| Amarin Corporation plc | -50.9 Million USD | 348.431% |
| Mesoblast Limited | -61.33 Million USD | 306.184% |
| Turnstone Biologics Corp. | -56.23 Million USD | 324.873% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 188.306% |
| Synaptogenix, Inc. | -8.3 Million USD | 1622.177% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 924.402% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 300.573% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 2739.171% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -29374.011% |
| Exelixis, Inc. | 196.6 Million USD | 35.68% |
| Better Therapeutics, Inc. | -38.26 Million USD | 430.498% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 189.425% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 125.536% |
| NLS Pharmaceutics AG | -11.79 Million USD | 1172.047% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -51051.624% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 528.574% |
| Gritstone bio, Inc. | -126.86 Million USD | 199.678% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 294.591% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 3261.418% |
| Avid Bioservices, Inc. | -11.48 Million USD | 1201.428% |
| Insmed Incorporated | -654.73 Million USD | 119.314% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 5720.924% |
| MediWound Ltd. | -4.89 Million USD | 2684.406% |
| OmniAb, Inc. | -49.73 Million USD | 354.278% |
| Alector, Inc. | -142.89 Million USD | 188.497% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 248.015% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 342.493% |
| Zai Lab Limited | -366.57 Million USD | 134.497% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 143.51% |
| Aura Biosciences, Inc. | -83.69 Million USD | 251.088% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 156.14% |
| Immunic, Inc. | -99.11 Million USD | 227.588% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 196.039% |
| Veracyte, Inc. | -49.4 Million USD | 355.935% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 1890.151% |
| FibroGen, Inc. | -261.4 Million USD | 148.375% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 1235.042% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 1906.157% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 775.621% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 91.275% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 597.423% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -217.009% |
| TG Therapeutics, Inc. | 26.1 Million USD | -384.502% |
| Galecto, Inc. | -37.51 Million USD | 437.043% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 430.472% |
| Fortrea Holdings Inc. | 167.3 Million USD | 24.414% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 194.173% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 546.664% |
| XBiotech Inc. | -35.76 Million USD | 453.562% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 294.591% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 293.801% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 221.062% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 592.579% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 409.431% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 124.485% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 325.728% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 225707.036% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 208.699% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 670.399% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 153.796% |
| NexImmune, Inc. | -28.16 Million USD | 548.939% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 2388.551% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 1172.355% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 97.283% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 598.011% |
| Scopus BioPharma Inc. | -11.71 Million USD | 1179.599% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 200.484% |
| Ainos, Inc. | -8.77 Million USD | 1541.395% |
| Pluri Inc. | -20.22 Million USD | 725.241% |
| Prothena Corporation plc | -190.1 Million USD | 166.517% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 198.64% |
| Celularity Inc. | -183.94 Million USD | 168.746% |
| Rallybio Corporation | -72.37 Million USD | 274.727% |
| Cue Biopharma, Inc. | -46.05 Million USD | 374.592% |
| MeiraGTx Holdings plc | -57.05 Million USD | 321.649% |
| Omeros Corporation | -163.61 Million USD | 177.291% |
| Humacyte, Inc. | -96.45 Million USD | 231.099% |
| Immunocore Holdings plc | -59.64 Million USD | 311.999% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 752.772% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 619.003% |
| Blueprint Medicines Corporation | -474.61 Million USD | 126.644% |
| CalciMedica, Inc. | -34.18 Million USD | 469.87% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 272.673% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 200.763% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 175.069% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 150.103% |
| Pulmatrix, Inc. | -12.64 Million USD | 1099.96% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 483.592% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 242.94% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 124.976% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 224.937% |
| Cytokinetics, Incorporated | -456.68 Million USD | 127.69% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 478.914% |
| Nutriband Inc. | -5.12 Million USD | 2568.967% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 392.233% |
| Vor Biopharma Inc. | -114.37 Million USD | 210.566% |
| Roivant Sciences Ltd. | -996.51 Million USD | 112.69% |
| Evogene Ltd. | -23.2 Million USD | 644.971% |
| ProKidney Corp. | -147.66 Million USD | 185.634% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 295.948% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 82669.916% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 122.363% |
| CorMedix Inc. | -48.88 Million USD | 358.668% |
| BioLineRx Ltd. | -57.06 Million USD | 321.614% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 213.151% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 62701.485% |
| Atai Life Sciences N.V. | -36.31 Million USD | 448.255% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 259.029% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 255.516% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 145.9% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 511.37% |
| MediciNova, Inc. | -9.87 Million USD | 1379.913% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 200.408% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 8363.947% |
| GeoVax Labs, Inc. | -26.66 Million USD | 574.169% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 156.204% |
| Biomea Fusion, Inc. | -124.62 Million USD | 201.472% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 138.28% |
| Mereo BioPharma Group plc | -26.05 Million USD | 585.32% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 166.437% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 154.994% |
| Absci Corporation | -95.45 Million USD | 232.473% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 521.166% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 218.052% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 154.162% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 653.292% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 160.844% |
| Allakos Inc. | -189.91 Million USD | 166.585% |
| Imunon, Inc. | -19.87 Million USD | 736.147% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 216.557% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -16.738% |
| BioAtla, Inc. | -122.24 Million USD | 203.447% |
| NLS Pharmaceutics AG | -11.79 Million USD | 1172.047% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 902.329% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 142.111% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 405.1% |
| XOMA Corporation | -39.36 Million USD | 421.262% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 227.405% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 207.484% |
| aTyr Pharma, Inc. | -52.17 Million USD | 342.353% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 250.874% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 185.08% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 153.91% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 1026.207% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 1672.374% |
| Akari Therapeutics, Plc | -16.8 Million USD | 852.619% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -66911.648% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 72.02% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 2079.377% |
| UroGen Pharma Ltd. | -63.83 Million USD | 298.109% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 286.196% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 1841.082% |
| Orgenesis Inc. | -60.71 Million USD | 308.266% |
| Entera Bio Ltd. | -8.8 Million USD | 1536.336% |
| GH Research PLC | -41.15 Million USD | 407.28% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 595.533% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 253.776% |
| Xencor, Inc. | -125.87 Million USD | 200.462% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 8964.424% |
| Replimune Group, Inc. | -230.19 Million USD | 154.933% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 727.331% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 1255.685% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 2079.377% |
| Portage Biotech Inc. | -18.19 Million USD | 794.846% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 8363.947% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 220.912% |
| OncoCyte Corporation | -23.12 Million USD | 646.88% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1219.035% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 1203.751% |
| Purple Biotech Ltd. | -22.22 Million USD | 668.976% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 2072.777% |
| scPharmaceuticals Inc. | -46.06 Million USD | 374.538% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 810.035% |
| HilleVax, Inc. | -132.46 Million USD | 195.462% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 1289.269% |
| Tharimmune, Inc. | -9.3 Million USD | 1459.353% |
| Genprex, Inc. | -31.06 Million USD | 507.124% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 167.433% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 503.314% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 16651.702% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -83698.309% |
| OKYO Pharma Limited | -15.74 Thousand USD | 803199.479% |
| Savara Inc. | -59.13 Million USD | 313.848% |
| Curis, Inc. | -45.13 Million USD | 380.146% |
| Daré Bioscience, Inc. | -30.7 Million USD | 511.885% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 932.426% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 1864.899% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 573.012% |
| BeiGene, Ltd. | -1.12 Billion USD | 111.244% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 875.74% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 129.368% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 239.977% |
| Erasca, Inc. | -121.31 Million USD | 204.241% |
| bluebird bio, Inc. | -167.16 Million USD | 175.649% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 2910.888% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 59.245% |
| DBV Technologies S.A. | -85.98 Million USD | 247.071% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 2910.888% |
| Moderna, Inc. | -3.28 Billion USD | 103.852% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 396.78% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 2338.934% |
| Molecular Templates, Inc. | 1.43 Million USD | -8743.007% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 311.279% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 138.761% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 192.243% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 366.974% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 190.953% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 161.428% |
| MacroGenics, Inc. | 2.01 Million USD | -6169.46% |
| RenovoRx, Inc. | -11.39 Million USD | 1210.228% |
| Adicet Bio, Inc. | -136.53 Million USD | 192.617% |
| Prime Medicine, Inc. | -193.75 Million USD | 165.264% |
| Aditxt, Inc. | -25.45 Million USD | 596.721% |
| Adagene Inc. | -14.95 Million USD | 945.808% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1829.867% |
| Quantum-Si incorporated | -91.8 Million USD | 237.745% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 82.25% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| SciSparc Ltd. | -5.28 Million USD | 2494.074% |
| Vericel Corporation | 2.86 Million USD | -4315.328% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 132919.721% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 682.972% |
| Generation Bio Co. | -133.3 Million USD | 194.865% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 252.3% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 247.001% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 155.601% |
| Invivyd, Inc. | -196.61 Million USD | 164.316% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 133.798% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 1463.426% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -365.696% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 1329.509% |
| 2seventy bio, Inc. | -206.41 Million USD | 161.262% |
| ADMA Biologics, Inc. | 5.12 Million USD | -2369.824% |
| Clene Inc. | -43.24 Million USD | 392.442% |
| Capricor Therapeutics, Inc. | -23 Million USD | 649.59% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 360.856% |
| GeoVax Labs, Inc. | -26.66 Million USD | 574.169% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 142.213% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 444.289% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -436.44% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -2475.324% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 489.308% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 179.831% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 118.479% |
| Evaxion Biotech A/S | -21.4 Million USD | 690.828% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 290.401% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 158.095% |
| Trevena, Inc. | -35.28 Million USD | 458.351% |
| Surrozen, Inc. | -41.13 Million USD | 407.445% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 258.879% |
| Cingulate Inc. | -22.95 Million USD | 650.953% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 1794.88% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 439.176% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 1637.191% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 223.653% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 286.438% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 316.636% |
| Clearmind Medicine Inc. | -8.71 Million USD | 1551.727% |
| Kronos Bio, Inc. | -121.83 Million USD | 203.796% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 270.099% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 5279.58% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 225.418% |
| Statera Biopharma, Inc. | 38.93 Million USD | -224.785% |
| ImmunityBio, Inc. | -436.18 Million USD | 128.991% |
| Korro Bio, Inc. | -80.9 Million USD | 256.303% |
| Kineta, Inc. | -15.71 Million USD | 904.728% |
| BioVie Inc. | -31.95 Million USD | 495.788% |
| Codexis, Inc. | -49.28 Million USD | 356.589% |
| Celularity Inc. | -183.94 Million USD | 168.746% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 157.088% |
| Celcuity Inc. | -58.3 Million USD | 316.867% |
| Virax Biolabs Group Limited | -6.6 Million USD | 2013.334% |
| Cibus, Inc. | -314.58 Million USD | 140.197% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 474.87% |
| IN8bio, Inc. | -28.5 Million USD | 543.639% |
| Kodiak Sciences Inc. | -259.02 Million USD | 148.82% |
| Annexon, Inc. | -141.57 Million USD | 189.32% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 212.306% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 296.983% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 552.352% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 154.978% |
| Eyenovia, Inc. | -24.1 Million USD | 624.578% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -182.366% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 39129.321% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 271.339% |
| Arcellx, Inc. | -64.14 Million USD | 297.139% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 380.924% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 202.413% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 509.478% |
| Moolec Science SA | -52.07 Million USD | 342.83% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 345.039% |
| Geron Corporation | -174.78 Million USD | 172.35% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 412.876% |
| Royalty Pharma plc | 1.88 Billion USD | 93.3% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 205.738% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1456.194% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 709.693% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 176.141% |
| Humacyte, Inc. | -96.45 Million USD | 231.099% |
| Structure Therapeutics Inc. | -102.45 Million USD | 223.42% |
| 89bio, Inc. | -134.46 Million USD | 194.044% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 260.323% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -3020.805% |
| Genelux Corporation | -24.16 Million USD | 623.298% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 474.127% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 177.36% |
| Notable Labs, Ltd. | -14.4 Million USD | 978.16% |
| Liquidia Corporation | -70.05 Million USD | 280.518% |
| Mustang Bio, Inc. | -48.06 Million USD | 363.103% |
| Immunovant, Inc. | -269.97 Million USD | 146.839% |
| Quantum-Si incorporated | -91.8 Million USD | 237.745% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 278.141% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 754.936% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 223.961% |
| Acasti Pharma Inc. | -11.3 Million USD | 1218.972% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 668.254% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 924.837% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 160.07% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 3061.238% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 896.316% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 539.446% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 441.493% |
| PepGen Inc. | -83.58 Million USD | 251.295% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 528.603% |
| United Therapeutics Corporation | 1.38 Billion USD | 90.882% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 652.278% |
| Solid Biosciences Inc. | -93.43 Million USD | 235.342% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 2750.084% |
| Immuneering Corporation | -58.06 Million USD | 317.798% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -3942993.234% |
| Silo Pharma, Inc. | -3.62 Million USD | 3587.246% |
| Belite Bio, Inc | -31.52 Million USD | 501.075% |
| XOMA Corporation | -39.36 Million USD | 421.262% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 287.488% |
| Bionomics Limited | -9.83 Million USD | 1385.504% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 250.569% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 465.414% |
| uniQure N.V. | -253.1 Million USD | 149.962% |
| Cassava Sciences, Inc. | -95.68 Million USD | 232.155% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1829.867% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 197.646% |
| Forte Biosciences, Inc. | -32.47 Million USD | 489.368% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 1670.777% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 548.12% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 39129.321% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 1235.042% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 895.264% |
| Altimmune, Inc. | -87.93 Million USD | 243.805% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 237.333% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 465.414% |
| Compugen Ltd. | -12.51 Million USD | 1110.347% |
| Peak Bio, Inc. | -1356.23 USD | 9324108.465% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 360.206% |
| Benitec Biopharma Inc. | -22.49 Million USD | 662.272% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 152.189% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 543.033% |
| Zura Bio Limited | -60.56 Million USD | 308.799% |
| PolyPid Ltd. | -20.26 Million USD | 724.068% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 909.934% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 543.033% |
| Instil Bio, Inc. | -146.12 Million USD | 186.541% |
| argenx SE | -216.02 Million USD | 158.538% |
| Immunome, Inc. | -28.27 Million USD | 547.296% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 360.877% |
| Verona Pharma plc | -52.46 Million USD | 341.015% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 233.431% |
| Shattuck Labs, Inc. | -87.61 Million USD | 244.33% |
| CervoMed Inc. | -2.17 Million USD | 5922.391% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 203.445% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 1096.258% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 362.496% |
| Moolec Science SA | -52.07 Million USD | 342.83% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 837.778% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 196.981% |
| AnaptysBio, Inc. | -143.16 Million USD | 188.329% |
| Design Therapeutics, Inc. | -66.32 Million USD | 290.66% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 256.142% |
| NeurAxis, Inc. | -6.66 Million USD | 1997.443% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 434.98% |
| Lumos Pharma, Inc. | -36.57 Million USD | 445.789% |
| Achilles Therapeutics plc | -70.44 Million USD | 279.516% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 233.431% |
| 180 Life Sciences Corp. | -22.13 Million USD | 671.315% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -2069.32% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 5279.58% |
| Nutriband Inc. | -5.12 Million USD | 2568.967% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 215.223% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 328.126% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 350.158% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 293.721% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 333.7% |
| Palisade Bio, Inc. | -12.28 Million USD | 1129.68% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 378.683% |
| Beam Therapeutics Inc. | -156.47 Million USD | 180.816% |
| Neurogene Inc. | -52.28 Million USD | 341.853% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 192.648% |
| AEON Biopharma, Inc. | -48.36 Million USD | 361.481% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 235.947% |
| Sesen Bio, Inc. | -50.84 Million USD | 348.731% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 254.341% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 1123.925% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 129.585% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 220.208% |
| Athira Pharma, Inc. | -116.7 Million USD | 208.356% |
| Vaccinex, Inc. | -19.74 Million USD | 740.343% |
| HCW Biologics Inc. | -23.57 Million USD | 636.37% |
| XOMA Corporation | -39.36 Million USD | 421.262% |
| Nektar Therapeutics | -243.1 Million USD | 152.016% |
| Arvinas, Inc. | -394.8 Million USD | 132.03% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -66911.648% |
| Merus N.V. | -149.2 Million USD | 184.751% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 235.26% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 504.527% |
| Rezolute, Inc. | -68.42 Million USD | 284.814% |
| Clene Inc. | -43.24 Million USD | 392.442% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 919.955% |
| BeyondSpring Inc. | -21.54 Million USD | 687.071% |
| Synlogic, Inc. | -55.16 Million USD | 329.247% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 1146.553% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 1288.263% |
| Peak Bio, Inc. | -1356.23 USD | 9324108.465% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 489.512% |
| Krystal Biotech, Inc. | 17.9 Million USD | -606.295% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 206.782% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 137.046% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 2845.183% |
| MannKind Corporation | 15.12 Million USD | -735.845% |
| Ikena Oncology, Inc. | -74.39 Million USD | 269.973% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 1104.169% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -522.104% |
| Gossamer Bio, Inc. | -172.15 Million USD | 173.455% |
| CohBar, Inc. | -12.06 Million USD | 1148.048% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 595.727% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 521.166% |
| Legend Biotech Corporation | -477.87 Million USD | 126.462% |
| Mural Oncology plc | -192.72 Million USD | 165.616% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 210.873% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 883.232% |
| Disc Medicine, Inc. | -91.02 Million USD | 238.923% |
| Champions Oncology, Inc. | -5.05 Million USD | 2602.078% |
| REGENXBIO Inc. | -239.46 Million USD | 152.808% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 1279.817% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 326.801% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 426.182% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 212.1% |
| Vaxart, Inc. | -74.72 Million USD | 269.232% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 459.163% |
| Cellectis S.A. | -98.09 Million USD | 228.911% |
| Longeveron Inc. | -20.06 Million USD | 730.384% |
| Repare Therapeutics Inc. | -114.27 Million USD | 210.66% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 128.792% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 269.03% |
| Revolution Medicines, Inc. | -430.58 Million USD | 129.368% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 2110.733% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 510.715% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 269.533% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -2479.135% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 1253.26% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 97.254% |
| Denali Therapeutics Inc. | -179.97 Million USD | 170.263% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 132919.721% |
| Veru Inc. | -89.97 Million USD | 240.544% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 570.478% |
| Cingulate Inc. | -22.95 Million USD | 650.953% |
| Passage Bio, Inc. | -98.34 Million USD | 228.588% |
| Context Therapeutics Inc. | -25.06 Million USD | 604.597% |
| Exicure, Inc. | -15.53 Million USD | 913.791% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 161.367% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 441.992% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 2220.804% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 175.064% |
| Nuvalent, Inc. | -149.49 Million USD | 184.59% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 1654.95% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 247.222% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 519.03% |
| OmniAb, Inc. | -49.73 Million USD | 354.278% |
| Anew Medical, Inc. | -1.3 Million USD | 9821.026% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 1122.768% |
| Lipocine Inc. | -16.32 Million USD | 874.72% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 289.673% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 270.188% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 431.614% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 424.127% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 670.054% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 123.2% |
| Ocugen, Inc. | -64.82 Million USD | 295.065% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 236.605% |
| Q32 Bio Inc. | -86.5 Million USD | 246.187% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 847.061% |
| Alumis Inc. Common Stock | -156.89 Million USD | 180.601% |
| Equillium, Inc. | -12.13 Million USD | 1141.811% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 316.266% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 1700.018% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 770.458% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 370.828% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 218.91% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 806.982% |
| Dominari Holdings Inc. | -22.44 Million USD | 663.525% |
| Edesa Biotech, Inc. | -8.19 Million USD | 1643.99% |
| vTv Therapeutics Inc. | -25.41 Million USD | 597.619% |
| Bio-Techne Corporation | 326.66 Million USD | 61.289% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 132.857% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 41.561% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 196.451% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 437.835% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 183.689% |
| Nkarta, Inc. | -120.48 Million USD | 204.958% |
| BioCardia, Inc. | -11.56 Million USD | 1193.901% |
| Iterum Therapeutics plc | -34.58 Million USD | 465.688% |